Bristol Myers Squibb Co (BMY) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
No intraday reading yet this session.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
5 readings, 3 filed under bull and 2 under bear. Every figure is ours; the model chose the side.
the bull case· 3
16
customers naming BMY as a supplier in their own filings
sec filingsfrom their filings10
of the funds on file reporting a position in BMY
n-portas of Jun 30 '2667
managers whose positions together make up four fifths of the reported value
13fJun 30 '26the bear case· 2
4 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized5 of 22
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26The model filed each reading under bull or bear and wrote its caption; a caption carrying a digit is replaced by our own phrase, so every figure on this zone is ours. Built Sep 16 '26 against the Oct 29 '26 report; rebuilt when that date rolls. Not a forecast, not advice.
2,530 managers report a position worth $98.8B between them, and 67 of them hold 80% of it.
tall tick = annual report · 1 on record
Bristol Myers Squibb Co
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Pharmaceutical Preparations
Of the 6 companies Bristol Myers Squibb Co moves with most closely, 2 also share its SEC classification.
Measured against 499 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
A rule beside a ticker marks a company that appears in both readings.
Which of these the filings never mention ›BMY (Bristol Myers Squibb Co) has 15 disclosed suppliers and 16 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move, and a bundle sits past the rings until you open it. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: NBP +8.18%, in the health bundle.